🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#TumorBoardTuesday We are coming to the end of #PancreaticCancer Awareness Month💜 📢Join us Tuesday, 11-28-23 at 8PM ET as Kevin Soares & Matthew McMillan, MD 🗣️mRNA🧬vaccines as treatment for #PancreaticCancer RT and bring others into the discussion‼️

The U.S. FDA has granted accelerated approval for our therapy for advanced melanoma. Learn more: ir.iovance.com/news-releases/…

Listening 2023 Bethesda system for reporting thyroid #cytopathology Syed Z. Ali 👏🏻 Turkish Cytopathology #10thnationalcongressofcytopathology

Precision medicine for #PancreaticCancer: Characterizing the clinico-genomic landscape and outcomes of KRAS G12C-mutated disease In JNCI from Wungki Park, MD MS Eileen M O’Reilly Rona Yaeger & colleagues Memorial Sloan Kettering Cancer Center ~1% of pancreatic cancers harbor G12C and may have a

Olaylar Ve Görüşler: Mesane kanseri tedavisi - Dr. Dilara Akbulut cumhuriyet.com.tr/yazarlar/olayl…

I would absolutely love to see a traditionally cold tumor become sensitive to immunotherapy (hot PDAC summer?)

Beyond proud of my mentor Wungki Park, MD MS for an incredible presentation at #ASCO2024 !! So lucky to learn from and work with you 😊💜Eileen M O’Reilly Mary Helen Larsen Fergus Keane Drew Moss

Interested to learn about #RNAVaccines for #cancer? Our thoughts now in Cancer Cell RNA Vaccines for cancer: Principles to Practice cell.com/cancer-cell/ab… Free pdf is here 👇🏽 authors.elsevier.com/a/1jDHe5TA51hO…

🔬Incorporating Molecular Data in Gastroesophageal and Pancreaticobiliary Cancers ASCO Educational Book ✅GE: HER2, Claudin 18.2, PD-L1, MSI ✅Biliary: FGFR2, IDH1, HER2, PD-L1 ✅Pancreatic: BRCA1-2/PALB2, Claudin 18.2 ✅Contemporary trials 👇 ✅Clinical trial design

Paper out!📢 Anupriya Singhal and #HannahStyers from the lab find acute resistance to targeting KRAS in pancreas cancer is surprisingly driven by a classical epithelial state. Co-targeting classical cells and KRAS augments response - clinically important! aacrjournals.org/cancerdiscover…

Cerebrospinal fluid revealing large, mitotically active cells. What is the diagnosis? Answer: buff.ly/3tOGWfM #PathArt #PathTwitter #MedTwitter #CytoPath

The FDA just approved the immunotherapy afami-cel for adults with #synovial sarcoma based on a trial led by Memorial Sloan Kettering Cancer Center's Sandra P D'Angelo, MD. Fantastic news for patients! mskcc.org/news/immunothe…

Macroscopy under the microscope: a free 2-day webinar 16-17 October 2024. Registration is mandatory. The registration links to follow. Hannah Wen Laura Collins Edi Brogi Samson W. Fine, MD Luis Z. Blanco Jr., MD (he/him) 🔬

Pleased to share our experience of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma ESMO - Eur. Oncology Gastrointestinal Oncology. 97.5% success rate using biopsy samples with median turn around time of 7 days. esmogastro.org/article/S2949-…

Distinct clinical outcomes & biological features of specific KRAS mutants in human pancreatic cancer Cancer Cell doi.org/10.1016/j.ccel… 👉KRASG12R enriched in early stage w/ reduced nodal disease + distant recurrence 👉improved OS 🧐 Supports KRAS mutational testing in #PDAC

#FIC ! #KRAS #G12D protein #degrader evaluated in heavily treated PDAC in 3L+ setting. Responses in non-chemotherapeutic backbone in this setting is not expected so this very encouraging! Thanks for sharing! #ESMO24 ESMO - Eur. Oncology MSK Department of Medicine MSKCC Center for Pancreatic Cancer Research

Claudin 18.2 immunohistochemistry is new for gastric and esophageal adenocarcinomas. Benign gastric mucosa is the internal positive control. 2+-3+ membrane staining in ≥75% of tumor cells is the cutoff for use of anti-CLDN18.2 (zolbetuximab). #UMiamiPath PMID: 39098518.